VGX Pharmaceuticals grants VGX International to exclusive license for VGX-1027

Published: 2008-03-03 06:56:00

Updated: 2008-03-03 06:56:00

VGX International announced on February 28 it has granted VGX International an exclusive license to its VGX-1027, lead drug candidate for the treatment of rheumatoid arthritis (RA) and type 1 diabetes (T1D).

VGX-1027 is a novel orally-active, small-molecule compound with broad anti-inflammato...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK